Cameron Santoro

Merilog (insulin-aspart-szjj) is the first rapid-acting insulin biosimilar to Novolog (insulin aspart) that is designated to improve glycemic control in adults and adolescents with type 2 diabetes.

The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to improve care, reduce costs, and address health equity for patients with skin diseases.

The FDA approved Ospomyv and Xbryk, denosumab biosimilars that could expand access to treatment for osteoporosis, cancer-related bone loss, and other endocrine diseases.

To maintain a healthy heart, researchers say people should focus on diet and exercise, limit alcohol, manage stress, get enough sleep, and more.

New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable treatment option for patients.

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into practice due to high costs and a lack of targeted initiatives to aid health care providers with integration.

The introduction of insulin glargine biosimilars is associated with significant price reductions across European markets.

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep behaviors.

Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals and the remaining challenges.

The removal of FDA guidance on clinical trial diversity and related anti–diversity, equity, and inclusion (DEI) actions may hinder progress toward equitable health care, impacting workforce diversity, patient outcomes, and research.

Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care providers to balance quality patient care with rising costs by openly discussing financial implications with patients and educating themselves on cost-effective treatments.

Early adult death in the US has significantly increased since 2010, with mortality rates exceeding prepandemic levels, even in 2023.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining functional independence.

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient and system costs by optimizing the use of generics and biosimilars, which offer lower costs without compromising safety and efficacy.

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help prevent tissue damage among these patients.

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis for up to 52 weeks.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch.

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars have grown more slowly.

Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar market entry.

The Affordable Care Act (ACA) led to reductions in out-of-pocket costs and improvements in health among adults entering Medicare.

An increased public interest and support for medication abortion following the federal Supreme Court ruling, particularly among marginalized groups, suggests a shift towards more accessible and autonomous models of abortion care.

The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.

Increased eczema risks in certain populations were associated with moderately high calcium intake, although pregnant women were found to potentially benefit from higher calcium consumption.

A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially benefit from shorter or less-intensive treatment.

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for patients, especially those who experience loss of response.

For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a potentially cost-effective access point to dermatological care.

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

Vitiligo, a skin condition causing depigmentation, may significantly increase the risk of serious cardiovascular events.

The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.